Article

Isis appoints Dr. Jonas as executive vice president

Carlsbad, CA-Jeffrey M. Jonas, MD, joined Isis Pharmaceuticals Inc. Feb. 1 as executive vice president. He will lead clinical development, preclinical development, regulatory affairs, quality assurance, and compliance at the company.

Carlsbad, CA-Jeffrey M. Jonas, MD, joined Isis Pharmaceuticals Inc. Feb. 1 as executive vice president. He will lead clinical development, preclinical development, regulatory affairs, quality assurance, and compliance at the company.

Dr. Jonas will be broadly responsible for the entire pipeline, both partnered and unpartnered, and contribute to portfolio management. In addition, he will be a principal representative of the company, interacting with investors and partners, working with Kate Corcoran, PhD, vice president, corporate development.

Prior to joining Isis, Dr. Jonas was chief medical officer and executive vice president at Forest Laboratories Inc., where he was responsible for clinical development, medical affairs, pharmacovigilence, and external scientific affairs.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
© 2025 MJH Life Sciences

All rights reserved.